指南与共识技术与安全介入PET

ACR-ACNM-ASTRO-SNMMI 镥-177(Lu-177)DOTATATE 治疗实践参数

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
指南 / 共识 · Clin Nucl Med · 2022-01-01

该实践参数由 ACR 两个实践参数委员会牵头,联合 ACNM、ASTRO、SNMMI 共同制定,旨在指导授权用户筛选适合接受 Lu-177 DOTATATE 肽受体放射性核素治疗的成人胃肠胰神经内分泌肿瘤(GEP-NET)患者,并规范药物安全操作、患者管理、治疗后监测与辐射安全告知。

要点

  • 筛选要点:生长抑素受体阳性、通常无法手术且标准治疗失败的成人 GEP-NET(前肠、中肠、后肠来源)。
  • Lu-177 DOTATATE 对肿瘤过表达的生长抑素受体具有高亲和力,可用于不可手术和/或晚期 GEP-NET。
  • 实践参数涵盖药理、适应证、不良反应、人员资质、治疗前临床评估、治疗后监测及辐射安全书面告知。

核心结论

  • Lu-177 DOTATATE 可用于常规治疗失败的不可手术和/或晚期 GEP-NET,能缩小肿瘤、改善症状并延长无进展生存期。
  • 该实践参数为授权用户提供临床指导,以保证 Lu-177 DOTATATE 治疗适当、一致且安全地实施。

研究设计与样本

  • 实践参数(指南/共识类文件),按照 ACR 网站所述的系统化流程制定。
  • 由 ACR 核医学与分子影像及放射肿瘤学两个实践参数委员会牵头,与 ACNM、ASTRO、SNMMI 合作制定。

诊断标准与关键数值

  • 基本筛选标准:生长抑素受体阳性的 GEP-NET,通常无法手术且尽管接受标准治疗仍进展。
  • 适用人群为前肠、中肠和后肠来源的胃肠胰神经内分泌肿瘤成人患者。

临床应用与阅片要点

  • 授权用户应确保 Lu-177 DOTATATE 的安全操作与受影响患者的安全管理。
  • 治疗前需完成所需临床评估,并遵循推荐的治疗后监测、质量保证与文档记录。
  • 应以书面形式向患者提供并解释适当的辐射安全指导。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) from foregut, midgut, and hindgut. The essential selection criteria include somatostatin receptor-positive GEP-NETs, which are usually inoperable and progressed despite standard therapy. Lu-177 DOTATATE is a radiopharmaceutical with high avidity for somatostatin receptors that are overexpressed by these tumors. This document ensures safe handling of Lu-177 DOTATATE by the authorized users and safe management of affected patients.

METHODS: The document was developed according to the systematic process developed by the American College of Radiology (ACR) and described on the ACR Web site (https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards). The PP development was led by 2 ACR Committees on Practice Parameters (Nuclear Medicine and Molecular Imaging and Radiation Oncology) collaboratively with the American College of Nuclear Medicine, American Society of Radiation Oncology, and Society of Nuclear Medicine and Molecular Imaging.

RESULTS: The Lu-177 DOTATATE PP reviewed pharmacology, indications, adverse effects, personnel qualifications, and required clinical evaluation before starting the treatment, as well as the recommended posttherapy monitoring, quality assurance, documentation, and appropriate radiation safety instructions provided in written form and explained to the patients.

CONCLUSIONS: Lu-177 DOTATATE is available for therapy of inoperable and/or advanced GEP-NETs when conventional therapy had failed. It can reduce tumor size, improve symptoms, and increase the progression free survival. The PP document provides clinical guidance for authorized users to assure an appropriate, consistent, and safe practice of Lu-177 DOTATATE.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Love C, Desai NB, Abraham T, et al. ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. Clin Nucl Med. 2022. PMID: 35507433. doi:10.1097/RLU.0000000000004182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。